RxDoctor Payments Data

Peaches Duon

Family · Pahrump, NVNPI 1326622788

Payments from drug & device makers

$1,476in general payments, 2019–2025

Across 66 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$384
  • Lilly USA, LLC$145
  • Lucid Diagnostics Inc.$121
  • Otsuka America Pharmaceutical, Inc.$100
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$97
  • Amgen$92
  • plus $537 from 14 others

What the payments were for

  • Food & beverage$1,476100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,476 in reported general payments places this provider in the 75th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$69,434
Medicare patients
164
Services billed
1,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$33,916
XareltoRivaroxaban23$32,296
TrulicityDulaglutide11$31,213
JardianceEmpagliflozin27$27,111
Albuterol Sulfate HfaAlbuterol Sulfate45$3,101
Levothyroxine Sodium106$1,542
Atorvastatin Calcium118$1,075
Gabapentin75$1,036
ValacyclovirValacyclovir Hcl16$1,023
Omeprazole51$984
Losartan Potassium75$875
Pregabalin15$848
Ibuprofen39$685
Pantoprazole Sodium55$650
Rosuvastatin Calcium50$589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$52$33,91618 claims
Lilly USA, LLCTrulicity$145$31,21311 claims
Boehringer IngelheimJardiance$46$27,11127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,501 family providers in Nevada.

Other family in Pahrump

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →